Benmelstobart
Phase 3Small molecule
Benmelstobart is one of 231 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.
8
Indications
9
Total Trials
9
Active Trials
230
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Benmelstobart
SSun Yat-sen University
Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neoadjuvant Therapy2 trials
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06699498·45 enrolled
Nasopharyngeal Carcinoma1 trial
3 more indications
Adjuvant Therapy1 trial
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT06955325·270 enrolled
Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Benmelstobart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSun Yat-sen University